Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

42 New Substances Among 84 EU Approval Recommendations In 2018

Executive Summary

The EMA’s CHMP recommended EU marketing authorization for a total of 84 new drugs in 2018, containing a total of 42 new active substances. They included the EU’s first two CAR-T cell therapies, Kymriah and Yescarta, which were also among the 21 orphan medicines to gain a positive opinion from the committee.
Advertisement

Related Content

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
New Filings At The EMA
European CHMP Opinions And MAA Updates
New EU Approvals
EMA Acts On Patient Concerns Over Fluoroquinolone Antibiotics
EMA Calls For Zinbryta's ‘Immediate’ Suspension After More Reports of Brain Disorders

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel